LB Pharmaceuticals, Inc. (LBRX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Paul Matteis.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Paul Matteis has given his Buy rating due to a combination of factors that highlight the potential of LB Pharmaceuticals, Inc.’s lead product, LB-102. The company’s strategy to develop LB-102, a methylated derivative of amisulpride, positions it well in the market for treating schizophrenia and bipolar depression. The strong phase 2 data for schizophrenia, coupled with a favorable safety profile, provides confidence in the drug’s potential success in phase 3 trials.
Furthermore, the anticipated phase 2 data for bipolar depression in 2028 presents a significant opportunity for upside, given the larger market potential compared to schizophrenia. The novel pharmacology of LB-102, along with its cleaner safety profile, suggests it could follow the successful commercial paths of similar drugs like Caplyta and Vraylar. These factors combined make LB-102 a promising candidate for blockbuster sales, justifying the Buy rating.
According to TipRanks, Matteis is a 5-star analyst with an average return of 14.7% and a 48.03% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Ionis Pharmaceuticals, and PepGen Inc..